hVIVO Past Earnings Performance
Past criteria checks 0/6
hVIVO has been growing earnings at an average annual rate of 44.6%, while the Life Sciences industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 13.2% per year.
Key information
44.60%
Earnings growth rate
45.50%
EPS growth rate
| Life Sciences Industry Growth | 36.86% |
| Revenue growth rate | 13.25% |
| Return on equity | -15.71% |
| Net Margin | -12.07% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Narrative Update • Mar 09
HVO: Human Challenge Platform Will Support Upgraded Earnings Conviction And Future Breakthroughs
Analysts have nudged their hVIVO price target higher to £0.29, citing slightly lower discount rate assumptions, modestly stronger revenue growth, improved profit margin expectations, and a small adjustment to the future P/E multiple. Analyst Commentary Recent Street research reflects a more positive tone around hVIVO, with bullish analysts pointing to a combination of valuation support and execution progress as reasons to reassess their stance.
Narrative Update • Feb 23
HVO: Lower Discount Rate And Strong Execution Will Support Future Rerating Potential
Narrative Update on hVIVO Analysts have lifted their price target on hVIVO to £0.18 per share, citing a modest change in the discount rate and updated future P/E assumptions as the main drivers of the revised view. Analyst Commentary Recent research points to a more constructive stance on hVIVO, with bullish analysts adjusting their assumptions around valuation multiples and discount rates to support the new £0.18 price target.Narrative Update • Feb 08
HVO: Expanded Respiratory Challenge Platform Will Support Future Upside Potential
Analysts have raised their fair value estimate for hVIVO from £0.17 to £0.18 per share, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the move from £0.17 to £0.18 per share as support for a slightly higher fair value range.Narrative Update • Jan 24
HVO: Long Term Antiviral Partnerships Will Support Future Upside Potential
Analysts have kept their fair value estimate for hVIVO broadly unchanged at £0.17 per share, with a slight adjustment in underlying assumptions, such as the discount rate and future P/E. This reflects updated views on risk and longer term earnings potential rather than a clear shift in the overall investment case.Narrative Update • Jan 10
HVO: Human Challenge Model Platform Will Support Future Respiratory Antiviral Breakthroughs
Analysts have trimmed their fair value estimate for hVIVO from £0.37 to £0.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and a higher future P/E multiple. What's in the News hVIVO highlighted its long running role in supporting Cidara Therapeutics' CD388 influenza programme, including early proof of concept human challenge work and ongoing Phase III support, after Cidara agreed to be acquired by Merck Sharp & Dohme for about US$9.2b (Key Developments).Narrative Update • Dec 24
HVO: Long Term Antiviral Partnership Will Drive Future Revenue Upside
Analysts have modestly raised their price target on hVIVO to reflect a slightly lower perceived risk profile and sustained expectations for robust long term revenue growth and profitability, while keeping fair value broadly unchanged at approximately £0.17 per share. What's in the News hVIVO highlighted its long term partnership with Cidara Therapeutics on CD388, an investigational long acting, strain agnostic antiviral for high risk influenza patients.Narrative Update • Dec 10
HVO: New Respiratory Challenge Models Will Drive Future Revenue Opportunities
Analysts have modestly raised their price target on hVIVO, citing a slightly higher assumed discount rate and marginally improved long term growth and valuation assumptions. Together, these factors support an updated fair value of approximately £0.17 per share.Narrative Update • Nov 26
HVO: Positive Data From New Models Will Drive Future Demand
Analysts have reduced their price target for hVIVO from £0.21 to £0.17. They cite slower expected revenue growth and tightening profit margins as key factors behind the adjustment.Narrative Update • Sep 24
Canary Wharf Expansion And Automation Will Improve Efficiency Despite Risks
Despite stronger revenue growth forecasts, a substantial decline in net profit margin has led to a notable reduction in hVIVO’s consensus analyst price target from £0.232 to £0.207. What's in the News hVIVO expects first-half 2025 revenues of £24.2 million.
New Narrative • Feb 09
Expansion Into New Canary Wharf Facility Will Increase Capacity But Challenges In Sustaining Margins May Arise
Expansion into a new facility and offering new services are expected to drive revenue growth and diversify income streams.Analysis Article • Jan 26
hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, hVIVO fair value estimate is UK£0.37 hVIVO's UK£0.29 share...Analysis Article • Jan 03
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified
The hVIVO plc ( LON:HVO ) share price has done very well over the last month, posting an excellent gain of 26%. The...Analysis Article • Nov 30
At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?
hVIVO plc ( LON:HVO ), is not the largest company out there, but it saw a decent share price growth in the teens level...Analysis Article • Jun 14
A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price
With a price-to-sales (or "P/S") ratio of 2.2x hVIVO plc ( LON:HVO ) may be sending bullish signals at the moment...Analysis Article • Feb 01
A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)
Key Insights hVIVO's estimated fair value is UK£0.1 based on 2 Stage Free Cash Flow to Equity Current share price of...Analysis Article • Dec 20
Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?
While hVIVO plc ( LON:HVO ) might not be the most widely known stock at the moment, it led the AIM gainers with a...Analysis Article • Sep 13
Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Open Orphan Plc...Analysis Article • Jun 02
Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?
How far off is Open Orphan plc ( LON:ORPH ) from its intrinsic value? Using the most recent financial data, we'll take...Analysis Article • Feb 15
Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Active investing isn't easy, but for those that do it, the aim is to find the best companies to buy, and to profit...Analysis Article • Dec 23
How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
Every investor in Open Orphan plc ( LON:ORPH ) should be aware of the most powerful shareholder groups. Institutions...Analysis Article • Nov 18
Calculating The Fair Value Of Open Orphan plc (LON:ORPH)
How far off is Open Orphan plc (LON:ORPH) from its intrinsic value? Using the most recent financial data, we'll take a...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How hVIVO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 50 | -6 | 0 | 0 |
| 30 Sep 25 | 52 | 0 | 0 | 0 |
| 30 Jun 25 | 54 | 5 | 0 | 0 |
| 31 Mar 25 | 60 | 8 | 0 | 0 |
| 31 Dec 24 | 66 | 11 | 0 | 0 |
| 30 Sep 24 | 67 | 14 | 0 | 0 |
| 30 Jun 24 | 67 | 17 | 0 | 0 |
| 31 Mar 24 | 63 | 17 | 0 | 0 |
| 31 Dec 23 | 59 | 16 | 0 | 0 |
| 30 Sep 23 | 60 | 9 | 0 | 0 |
| 30 Jun 23 | 60 | 3 | 0 | 0 |
| 31 Mar 23 | 56 | 1 | 0 | 0 |
| 31 Dec 22 | 51 | -1 | 0 | 0 |
| 30 Sep 22 | 43 | -1 | 0 | 0 |
| 30 Jun 22 | 35 | -1 | 0 | 0 |
| 31 Mar 22 | 37 | -1 | 0 | 0 |
| 31 Dec 21 | 39 | 0 | 0 | 0 |
| 30 Sep 21 | 39 | -2 | 1 | 0 |
| 30 Jun 21 | 39 | -3 | 1 | 0 |
| 31 Mar 21 | 30 | -7 | 1 | 0 |
| 31 Dec 20 | 22 | -11 | 2 | 0 |
| 30 Sep 20 | 16 | -11 | 1 | 0 |
| 30 Jun 20 | 10 | -11 | 1 | 0 |
| 31 Mar 20 | 7 | -8 | 0 | 0 |
| 31 Dec 19 | 3 | -6 | 0 | 0 |
| 30 Jun 19 | 0 | -2 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
Quality Earnings: HVO is currently unprofitable.
Growing Profit Margin: HVO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HVO is unprofitable, but has reduced losses over the past 5 years at a rate of 44.6% per year.
Accelerating Growth: Unable to compare HVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HVO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: HVO has a negative Return on Equity (-15.71%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 23:45 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
hVIVO plc is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Mitchell | Cavendish |
| Edward Thomason | CGS International |
| Colin Grant | Davy |